Economic Overview - The Estonian economy is experiencing a slow recovery with weak and unstable growth, and inflation remains high at 5.4% year-on-year as of July 2025, driven by rising taxes and increased expenditures on food and healthcare [1] - Consumer confidence is low due to rapid price growth, although lower interest rates and energy prices may improve confidence in the second half of the year [1] Loan Demand and Consumer Financing - There is strong growth in loan demand from private customers, with home loan turnover reaching a record-high of 268 million euros in June, influenced by a 2 percentage point increase in value-added tax starting in July [2] - Demand for consumer financing remains robust, driven by needs for home renovation, furnishing, and travel plans, while the car leasing portfolio saw a slight decrease [3] Banking Services and Customer Growth - Coop Pank introduced new daily banking packages, with the "Kasulik" package being the most popular, offering cashback on purchases at Coop stores, which helps attract new customers and activate existing ones [4] - The bank's client base increased by 1,700 in July, reaching a total of 219,300 clients, with active clients increasing by 600 to 104,100, marking an 11% growth over the year [6] Financial Performance - The volume of customer deposits rose by 111 million euros to 1.93 billion euros, with corporate deposits increasing by 50 million euros and private deposits by 2 million euros [6] - The bank's loan portfolio grew by 23 million euros to 1.97 billion euros, with business loans increasing by 10 million euros and home loans by 13 million euros [6] - Coop Pank reported a net profit of 2.4 million euros in July, with a year-to-date net profit of 16.9 million euros, reflecting a 16% decrease compared to the previous year [6][8] Strategic Developments - The bank raised 111 million euros in deposits in July to support strong loan growth, with nearly half coming from local customers and the remainder from the international deposit platform Raisin [7] - The bank aims to leverage the synergy between retail business and banking to enhance everyday banking services for customers [8]

Core Points - Sandoz has signed a 10-year virtual Power Purchase Agreement (PPA) with Elawan Energy for new solar projects in Spain, marking a significant step in its decarbonization strategy [1][8] - The partnership is expected to meet nearly 90% of Sandoz's current electricity demand across its European operations, with a total installed capacity of 150 MW for the new solar projects [2][3] Company Commitment - Sandoz emphasizes environmental sustainability as a core operational principle, reflecting its responsibility to the planet and its stakeholders [3] - The company has submitted a Commitment Letter to the Science Based Targets Initiative (SBTi) in 2024, indicating its intent to set science-based carbon emission reduction targets, with plans for validation submission by January 2026 [3] Operational Impact - The collaboration with Elawan Energy is part of Sandoz's ongoing efforts to decarbonize electricity use globally, complementing similar agreements for production operations across multiple sites [3] - In 2024, Sandoz reported net sales of USD 10.4 billion, highlighting its significant role in the global healthcare sector [6]

Core Insights - Tecan reported solid financial results for the first half of 2025, confirming its outlook for the full year despite ongoing market challenges [1][2] Financial Performance - Order entry for H1 2025 was CHF 458.3 million, a decrease of 2.9% year-on-year, but showed sequential improvement with mid-single-digit growth in Q2 [3] - Sales decreased by 5.9% in Swiss francs to CHF 439.5 million, with a decline of 3.7% in local currencies; however, there was a sequential improvement from Q1 to Q2 [4][5] - Adjusted EBITDA was CHF 65.7 million, with an improved margin of 15.0% despite lower sales volume [6] - Adjusted net profit was CHF 33.7 million, down from CHF 36.5 million in H1 2024, impacted by foreign exchange effects and a higher effective tax rate [7] Business Segment Analysis - Life Sciences Business sales were CHF 185.7 million, a slight decrease of 1.0% in Swiss francs but an increase of 1.6% in local currencies, supported by growth in clinical diagnostics [9][10] - Partnering Business sales were CHF 253.8 million, down 9.2% in Swiss francs, with strong growth in in-vitro diagnostics systems but a decline in Cavro OEM components [12][13] Operational Highlights - Tecan enhanced operational resilience through cost-reduction programs and site consolidations, including the closure of two California sites [16][17] - Continued focus on innovation with new product launches such as Veya™ and FlowPilot, aimed at improving laboratory workflows [19][20] Share Buyback Program - Tecan announced a share buyback program of up to CHF 120 million, reflecting confidence in long-term growth prospects [26][27] Outlook for 2025 - Tecan confirmed its full-year sales outlook, expecting sales in local currencies to range from a low single-digit percentage decline to low single-digit percentage growth [29] - The company anticipates an adjusted EBITDA margin of 17.5% to 18.5% for the full year [30]

Core Viewpoint - Ligand Pharmaceuticals has announced a private placement of $400 million in 0.75% convertible senior notes due 2030, with an option for initial purchasers to buy an additional $60 million in notes, expected to close on August 14, 2025 [1][3]. Summary by Sections Offering Details - The notes will be general unsecured, senior obligations of Ligand, accruing interest at 0.75% per annum, payable semiannually starting April 1, 2026, and maturing on October 1, 2030 [2][3]. - Ligand estimates net proceeds from the offering to be approximately $386.9 million, or $445.1 million if the additional notes option is fully exercised [3]. Use of Proceeds - Approximately $39.9 million of the net proceeds will be used for convertible note hedge transactions, and $15 million will be allocated for repurchasing 102,034 shares of common stock at $147.01 per share [3][12]. - Remaining proceeds will be used for general corporate purposes, including potential investments in complementary businesses, although no commitments currently exist [3]. Conversion and Redemption - Holders can convert their notes under certain conditions before July 1, 2030, and thereafter until the second trading day before maturity [4]. - Upon conversion, Ligand will pay cash up to the principal amount and may pay the remainder in cash, shares, or a combination [5]. - The initial conversion rate is set at 5.1338 shares per $1,000 principal amount, equating to a conversion price of approximately $194.79 per share, representing a 32.5% premium over the last reported sale price [5]. Redemption Terms - Ligand may redeem the notes starting October 6, 2028, if the stock price meets certain conditions, at a redemption price equal to 100% of the principal amount plus accrued interest [6]. Fundamental Change and Hedges - In the event of a fundamental change, holders may require Ligand to repurchase their notes at 100% of the principal amount plus accrued interest [7][8]. - Ligand has entered into convertible note hedge transactions to reduce potential dilution upon conversion and has also issued warrants that could have a dilutive effect if the stock price exceeds the strike price of $294.02 per share [9][10]. Company Overview - Ligand Pharmaceuticals focuses on supporting the clinical development of high-value medicines through financing and licensing technologies, aiming to create a diversified portfolio of biotech and pharmaceutical revenue streams [16].

Core Viewpoint - CubeSmart, the third-largest owner and operator of self-storage properties in the U.S., announced a public offering of $450 million in senior unsecured notes due 2035, with a yield to maturity of 5.295% [1][2]. Group 1: Offering Details - The offering consists of $450 million aggregate principal amount of 5.125% senior unsecured notes priced at 98.656% of the principal amount [1]. - The notes will be fully guaranteed by CubeSmart and are expected to close on August 20, 2025, subject to customary closing conditions [1][2]. - The proceeds from the offering will be used to repay outstanding indebtedness under the unsecured revolving credit facility and for general corporate purposes [2]. Group 2: Management and Underwriters - Wells Fargo Securities, BofA Securities, and PNC Capital Markets LLC are acting as joint book-running managers for the offering [3]. - Regions Securities LLC and US Bancorp are serving as senior co-managers, while several other firms are acting as co-managers [3]. Group 3: Company Overview - As of June 30, 2025, CubeSmart owned or managed 1,532 self-storage properties across the United States [6]. - CubeSmart is recognized as one of the top three owners and operators of self-storage properties in the U.S. according to the 2025 Self Storage Almanac [6]. - The company's mission focuses on simplifying organizational and logistical challenges for customers through innovative solutions and exceptional service [7].

Core Viewpoint - Fairfax Financial Holdings Limited intends to offer C$400 million in Senior Notes due 2035 and C$300 million in Senior Notes due 2055, with fixed interest rates of 4.45% and 5.10% respectively, to refinance existing obligations and pursue investment opportunities [1][2]. Group 1: Offering Details - The total offering consists of C$400 million in 2035 Notes priced at C$99.824 per C$100 principal amount and C$300 million in 2055 Notes priced at C$99.619 per C$100 principal amount [1]. - The Senior Notes will be offered through a syndicate of dealers led by National Bank Financial Inc., RBC Dominion Securities Inc., Scotia Capital Inc., and TD Securities Inc. [1]. - The offering is expected to close on or about August 14, 2025, subject to customary conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to refinance, repay, or redeem outstanding debt, equity, or other corporate obligations of Fairfax and its subsidiaries [2]. - The proceeds may also be used for potential acquisitions or investments, including minority interests in subsidiaries, and for general corporate purposes [2]. - Specific determinations regarding the debt or equity to be repaid or the acquisitions to be pursued have not yet been made [2]. Group 3: Regulatory and Access Information - The Senior Notes will be offered in all provinces and territories of Canada under Fairfax's base shelf prospectus dated October 11, 2023 [3]. - Access to the shelf prospectus supplement and base shelf prospectus will be provided in accordance with Canadian securities legislation [3][4]. - Interested parties can obtain copies of the prospectus documents from the listed financial institutions [4].

Core Viewpoint - Prime Mining Corp. reported strong operational and financial results for Q2 2025, highlighting a significant increase in cash reserves and a proposed acquisition by Torex Gold, which offers immediate value to shareholders while reducing development risks [2][9]. Corporate Highlights During the Quarter - The company closed the quarter with CAD 32.7 million in cash and equivalents, a substantial increase from CAD 19.1 million at the end of 2024 [14]. - Prime Mining exercised 97% of its June warrants, contributing to the increase in cash reserves [2][14]. - The selection of Ausenco as the lead engineer for the Preliminary Economic Assessment (PEA) of the Los Reyes project was announced [3][8]. Project Highlights - The Los Reyes Gold-Silver Project is a high-grade, low-sulphidation epithermal project located in Sinaloa State, Mexico, with significant exploration activities ongoing [18]. - The company has invested CAD 66.7 million in direct exploration activities since acquiring Los Reyes in 2019, completing over 221,000 meters of drilling [18]. - An updated resource estimate as of October 15, 2024, indicated a total indicated resource of 1.49 million ounces of gold and 53.99 million ounces of silver [21][28]. Financial Performance - For the six months ended June 30, 2025, the company reported a loss of CAD 6.17 million, an improvement from a loss of CAD 11.94 million in the same period of 2024 [14]. - The loss per share decreased from CAD 0.08 in 2024 to CAD 0.04 in 2025 [14]. - Total assets increased to CAD 46.93 million from CAD 33.18 million at the end of 2024 [14]. Acquisition Details - On July 28, 2025, Prime Mining announced a definitive agreement for acquisition by Torex Gold, where shareholders will receive 0.060 of a Torex share for each Prime share held [10][11]. - The transaction is expected to close in the second half of 2025, subject to regulatory approvals and customary closing conditions [12][16]. Community Engagement and Environmental Stewardship - The company is actively engaged with local stakeholders and is committed to minimizing its environmental footprint while ensuring a positive impact on host communities [5][4]. - Prime Mining has released its inaugural sustainability report and is working on ESG programs to support community and environmental initiatives [6][5].

Delray Beach, FL, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Highview Merger Corp. (the “Company”) announced today that it priced its initial public offering of 20,000,000 units at a price of $10.00 per unit. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share. Only whole warrants will be exercisable. The units will be listed on The Nasdaq Global Market (“Nasdaq”) and trade under ...

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenhawk Resources Inc. (“Greenhawk” or the "Company") (CSE: GRHK) announces John Kennedy FitzGerald (“FitzGerald”), of Toronto, Ontario announces that on Friday, August 8, 2025 he acquired in part through the facilities of the Canadian Securities Exchange and in part through a private purchase and sale transaction, ownership and control over an aggregate of 10,233,333 common shares of the Company. Following these acquisitions, FitzGerald beneficially owns or exer ...

Core Viewpoint - Revive Therapeutics Ltd. has successfully closed the first tranche of its private placement offering, raising a total of $60,900 through the issuance of 2,900,000 units at a price of $0.021 per unit, while also settling a note payable through the issuance of additional units [1][2][3]. Group 1: Offering Details - The first tranche of the offering consisted of 2,900,000 units, generating gross proceeds of $60,900 for the company [1]. - Each unit comprises one common share and one common share purchase warrant, with the warrant allowing the holder to acquire one common share at an exercise price of $0.05 for 36 months [2]. - The company issued an additional 3,209,523 units to settle a note payable of $67,400, maintaining the same issue price of $0.021 per unit [1][3]. Group 2: Use of Proceeds - The gross proceeds from the offering will be allocated for working capital and the payment of certain trade payables [2]. Group 3: Compensation Options - In connection with the offering, the company issued 100,000 compensation options to an investment dealer, allowing the dealer to purchase units at a price of $0.05 for 18 months [4]. - Each compensation unit consists of one common share and one-half of a common share purchase warrant, with the whole warrant allowing acquisition of one compensation share at an exercise price of $0.05 for 36 months [5]. Group 4: Company Overview - Revive Therapeutics is focused on developing innovative therapeutics for critical medical needs, leveraging FDA regulatory incentives for rapid advancement and market entry [6]. - The company is currently concentrating on the potential of Bucillamine for infectious diseases and medical countermeasures, as well as advancing its Psilocybin and molecular hydrogen therapeutic programs [6].